Emicizumab-kxwh (Hemlibra)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

Mechanism of action

A recombinant, humanized, bispecific monoclonal antibody that bridges activated factor IX and factor X to restore the function of missing activated factor VIII.

Diseases for which it is used

History of changes in FDA indication

  • 11/16/2017: FDA approved "for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors."

Also known as

  • Code name: ACE910
  • Brand name: Hemlibra